Standout Papers
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials (2018)
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (2017)
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events (2017)
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus (2018)
Immediate Impact
3 from Science/Nature 107 standout
Citing Papers
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
2023 Standout
Gliflozins in the Management of Cardiovascular Disease
2022 Standout
Works of Wayne Shaw being referenced
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
2018 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Wayne Shaw | 6814 | 2919 | 1820 | 2670 | 36 | 8.1k | |
| Eri Kato | 5783 | 2396 | 1916 | 2397 | 45 | 7.2k | |
| Mehul Desai | 7621 | 3333 | 1903 | 3202 | 49 | 9.2k | |
| Thomas A. Zelniker | 6545 | 2725 | 2385 | 2744 | 67 | 8.4k | |
| Greg Fulcher | 7548 | 3312 | 1783 | 2847 | 62 | 9.2k | |
| Ingrid Gause‐Nilsson | 5914 | 2401 | 1585 | 2606 | 68 | 7.3k | |
| Hans J. Woerle | 8196 | 3447 | 2316 | 3407 | 24 | 9.7k | |
| Avivit Cahn | 7371 | 2872 | 1944 | 3007 | 111 | 8.8k | |
| Michael G. Silverman | 4282 | 2556 | 1924 | 1826 | 42 | 6.5k | |
| Julia Kuder | 4736 | 3409 | 3030 | 1865 | 59 | 8.4k | |
| Gordon Law | 5004 | 2058 | 1199 | 2081 | 12 | 6.1k |
All Works
Loading papers...